Neuronetics (STIM) Q3 2026 Earnings Call Transcript

Neuronetics reported Q3 2026 revenue of $42.0 million, up 12.5% year over year, and adjusted EBITDA of $1.9 million versus a $4.7 million loss a year earlier. Gross margin expanded to 52.2% from 45.9%, while operating and investing cash flow turned positive at $0.8 million; Greenbrook revenue rose 20.1% to $26.2 million. Management kept full-year revenue guidance at $160 million–$164 million, raised gross-margin guidance to 49%–50% from 48%–50%, and lowered operating-expense guidance to $92.5 million–$95.5 million. The company expects session revenue to trend slightly lower as it shifts NeuroStar toward capital and lease sales, and plans to add eight Greenbrook field sales representatives by Q1 2027 by reallocating advertising spend.

Analysis

STIM’s quarter improves the near-term credibility of its operating-turnaround story, but the earnings mix matters more than headline growth. Greenbrook’s gains combine better collections and Spravato growth; management describes some RCM benefits as durable, while acknowledging prior-period catch-ups are not. The 25%-to-75% clinic occupancy spread is the latent operating leverage—and the execution risk. Reallocated ad spend avoids planned incremental sales expense, but the new reps are not expected to contribute meaningfully until mid-2027.

NeuroStar capital/lease placements can support near-term gross margin as session revenue declines, but they shift exposure toward lumpy equipment demand and make the quarter’s margin a poor run-rate assumption. Full-year margin guidance remains below Q3’s level, so avoid extrapolating the print. Cash also deserves a quality check: $5.8 million of reported cash is restricted, and the company still guides to negative full-year operating and investing cash flow.

Over days, a favorable reaction is plausible; over 1–3 months, watch Q4 capital orders, clinic collections, and whether reduced marketing spend preserves patient starts. Over 6–18 months, accelerated-protocol clearance, broader EHR integrations, and COMPASS Pathways’ potential launch could expand the channel opportunity, but remain contingent—not booked growth. Contrarian risk: investors may treat one positive quarter as proof of durable profitability before occupancy improves and session declines stabilize. No valuation or share-price context is provided, so avoid chasing an opening gap.

Key Decisions for Investors

• STIM: Consider a small, tactical long only after the market confirms the earnings response (e.g., holds the post-report gap through the first session); use the report-day low as a thesis-failure reference. Do not annualize Q3 margin or assume positive cash generation persists.
• Over the next 1–3 months, track Greenbrook same-clinic patient volume/occupancy, collections excluding catch-ups, and NeuroStar capital orders versus session revenue. Reduce or exit the thesis if guidance is cut, collections reverse, or equipment demand weakens while sessions continue falling.
• Treat the FDA 510(k), incremental EHR integrations, and COMPASS-related clinic opportunity as watch items, not current earnings drivers. Verify FDA timing, reimbursement/coverage, pilot economics, and unrestricted cash before assigning material value to them.